ArticleCancer immunology research2026
Single-cell profiling of peripheral blood mononuclear cells in diverse men with prostate cancer reveals a fatal disease-associated immune signature.
Article in Cancer immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Alterations in peripheral immunity may contribute to fatal prostate cancer and the excessive disease burden among African American (AA) men. Thus, we investigated peripheral immunity in prostate cancer patients in association with disease outcome and AA descent. We performed single-cell RNA and T cell receptor (TCR) sequencing using peripheral blood mononuclear cells (PBMC) from a cohort of 43 prostate cancer patients with survival follow-up and 16 healthy controls. Analyzing 273,229 high-quality PBMC, we observed that men who developed fatal prostate cancer (n=20) distinctively expressed the LAG3 and TIGIT exhaustion markers in their CD8⁺ T effector memory cells (CD8 TEM). These men also showed a loss of type-2 conventional dendritic cells (cDC2). Further analyses revealed additional transcriptome-inferred functional differences in cDC2, CD16+ monocytes, and CD8 TEM comparing men with and without fatal disease. Those describe cDC2 as immunosuppressed, CD16+ monocytes as pro-inflammatory but less cytotoxic, and CD8 TEM as chronically activated in patients with fatal disease. Comparing AA with European American patients, we observed upregulated LAG3 and TIGIT in AA PBMC. For cDC2 and CD16+ monocytes, fatal disease and AA patients showed shared marker expression. Furthermore, TCR profiling discovered over-representation of large, hyperexpanded clonotypes and a lower TCR diversity among fatal disease and AA patients. Lastly, the CD8 TEM functional status and LAG3 expression in PBMC emerged as a candidate predictor of disease fatality. We conclude that peripheral immunity may distinctly vary in association with disease outcome and AA descent of prostate cancer patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.